Phase I/II trial of Velcade [bortezomib] + CHOP-rituximab in patients with previously untreated diffuse large B cell or mantle cell non-Hodgkin's lymphoma
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 23 Feb 2017 Status changed from active, no longer recruiting to completed.
- 05 Feb 2011 Preliminary results published in the Journal of Clinical Oncology, according to a Millennium: The Takeda Oncology Company media release.
- 27 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.